Pharmaceuticals · Projected milestone
Multiproduct cell-free therapeutic manufacturing
70% by 2042 · including earlier years
The year is an editorial timing estimate. The percentage applies to occurrence by the stated deadline. These estimates are not calibrated odds.
A common cell-free production platform makes three distinct therapeutic proteins whose independent batch tests meet preregistered potency, purity, sterility and stability specifications at clinically relevant dose quantities.
Explore this milestone on the interactive mapWhat the forecast means
Milestone stage: manufacturing validation
on-demand biomolecule production demonstrated; therapeutic release-quality integration unproven
Timing window: 2028–2040. An editorial range, not a statistical confidence interval.
Completion criteria: A common cell-free production platform makes three distinct therapeutic proteins whose independent batch tests meet preregistered potency, purity, sterility and stability specifications at clinically relevant dose quantities. Resolve only from inspectable evidence meeting every stated criterion; a plan or extrapolation does not resolve it.
This page describes a forecast, rather than an achieved result. Read the methodology and assumptions.
Built on
Led to
Sources & evidence
- Portable, On-Demand Biomolecular Manufacturing 2016
Freeze-dried cell-free machinery produced functional biomolecules; clinical release, sterility and manufacturing economics are separate milestones.
Astra editorial synthesis; cited researchers retain credit for their results
Record reviewed 2026-10-18